Seminars in Oncology
Volume 35, Issue 3 , Pages 298-308 , June 2008

Standard and Emerging Therapeutic Approaches for Thyroid Malignancies

  • Rebecca L. Brown

      Affiliations

    • Corresponding Author InformationAddress correspondence to Rebecca Brown, MD, Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Chicago, 5841 S Maryland Ave, Mail Code 1027, Chicago, IL 60645.

References 

  1. Patel KN, Singh B. Genetic considerations in thyroid cancer. Cancer Control. 2006;13:111–118
  2. Sosa JA, Udelsman R. Total thyroidectomy for differentiated thyroid cancer. J Surg Oncol. 2006;94:701–707
  3. American Cancer Society. http://www.cancer.org/docroot/home//2008
  4. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) program. http://seer.cancer.gov/2008
  5. Burgess JR, Tucker P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid. 2006;16:47–53
  6. Thyroid Carcinoma Task Force. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma (American Association of Clinical Endocrinologists). Endocr Pract. 2001;7:202–220
  7. Thyroid Carinoma. National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdfAccessed March 2007
  8. Green FL, Page DL, Fleming ID. AJCC cancer staging manual. 6th ed.. New York: Springer; 2002;
  9. Sherman SI, Brierley JD, Sperling M, et al. National Thyroid Cancer Treatment Cooperative Study Registry Group Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. Cancer. 1998;83:1012–1021
  10. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–428
  11. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109–142
  12. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050–1057
  13. DeGroot LJ, Kaplan EL, Straus FH, et al. Does the method of management of papillary thyroid carcinoma make a difference in outcome?. World J Surg. 1994;18:123–130
  14. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med. 1981;70:511–518
  15. Hay ID, Grant CS, Taylor WF. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102:1088–1095
  16. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447–1463
  17. Sosa JA, Bowman HM, Tielsch JM, et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998;228:320–330
  18. Lamade W, Renz K, Willeke F, et al. Effect of training on the incidence of nerve damage in thyroid surgery. Br J Surg. 1999;86:388–391
  19. Pal T, Vogl FD, Chappuis PO, et al. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab. 2001;86:5307–5312
  20. Shattuck TM, Westra WH, Ladenson PW. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med. 2005;352:2406–2412
  21. Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol. 2004;150:105–112
  22. Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid. 1997;7:613–619
  23. Robbins RJ, Tuttle RM, Sonenberg M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid. 2001;11:865–869
  24. Berg G, Lindstedt G, Suurkula M. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest. 2002;25:44–52
  25. Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab. 2003;88:4110–4115
  26. Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2002;87:4063–4068
  27. Park HM, Perkins OW, Edmondson JW, et al. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid. 1994;4:49–54
  28. Leger FA, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med. 1998;25:242–246
  29. Muratet JP, Daver A, Minier JF. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med. 1998;39:1546–1550
  30. Fatourechi V, Hay ID, Mullan BP, et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?. Thyroid. 2000;10:573–577
  31. Sherman SI, Tielens ET, Sostre S, et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab. 1994;78:629–634
  32. Grigsby PW, Siegel BA, Baker S, et al. Radiation exposure from outpatient radioactive iodine (131I) therapy for thyroid carcinoma. JAMA. 2000;283:2272–2274
  33. Doi SA, Woodhouse NJ. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin Endocrinol (Oxf). 2000;52:765–773
  34. Maxon HR. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med. 1999;43:313–323
  35. Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med. 2006;47:1587–1591
  36. Kulkarni K, Nostrand DV, Atkins F, et al. The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid. 2006;16:1019–1023
  37. Taylor T, Specker B, Robbins J, et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med. 1998;129:622–627
  38. Robbins RJ, Schlumberger MJ. The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med. 2005;46(Suppl 1):28–37
  39. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–2899
  40. Mazzaferri EL. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid. 1997;7:265–271
  41. DeGroot LJ, Kaplan EL, McCormick M, et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71:414–424
  42. Hay ID. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am. 1990;19:545–576
  43. Hay ID, Grant CS, van Heerden JA, et al. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery. 1992;112:1139–1146
  44. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879–885
  45. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16:1229–1242
  46. Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol. 2006;94:692–700
  47. Cady B. Seminars in surgical oncology on thyroid cancer. J Surg Oncol. 2006;94:646–648
  48. Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab. 2005;1:32–40
  49. Toft AD. Clinical practice (Subclinical hyperthyroidism). N Engl J Med. 2001;345:512–516
  50. Torlontano M, Attard M, Crocetti U, et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab. 2004;89:3402–3407
  51. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433–1441
  52. Spencer CA. Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metab. 2001;89:3702–3704
  53. Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:3668–3673
  54. Frasoldati A, Pesenti M, Gallo M, et al. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer. 2003;97:90–96
  55. Lima N, Cavaliere H, Tomimori E, et al. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer. J Endocrinol Invest. 2002;25:110–115
  56. Pacini F, Fugazzola L, Lippi F, et al. Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. J Clin Endocrinol Metab. 1992;74:1401–1404
  57. Salvatore G, Giannini R, Faviana P, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2004;89:5175–5180
  58. Chow SM, Yau S, Kwan CK, et al. Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition. Endocr Relat Cancer. 2006;13:1159–1172
  59. Lee N, Tuttle M. The role of external beam radiotherapy in the treatment of papillary thyroid cancer. Endocr Relat Cancer. 2006;13:971–977
  60. Ronga G, Filesi M, Montesano T, et al. Lung metastases from differentiated thyroid carcinoma (A 40 years' experience). Q J Nucl Med Mol Imaging. 2004;48:12–19
  61. Bernier MO, Leenhardt L, Hoang C, et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2001;86:1568–1573
  62. Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer. 2005;12:49–64
  63. Robbins RJ, Driedger A, Magner J. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid. 2006;16:1121–1130
  64. Schlumberger M, Lacroix L, Russo D, et al. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab. 2007;3:260–269
  65. Pacini F, Agate L, Elisei R, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab. 2001;86:4092–4097
  66. Pacini F, Lippi F, Formica N, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med. 1987;28:1888–1891
  67. Pineda JD, Lee T, Ain K, et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab. 1995;80:1488–1492
  68. Grunwald F, Schomburg A, Bender H, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1996;23:312–319
  69. Chin BB, Patel P, Cohade C, et al. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2004;89:91–95
  70. Holt E. Controversies in the surveillance of patients with well differentiated thyroid cancer. Curr Opin Oncol. 2007;19:6–10
  71. Bernstein L, Gurney JG. Carcinomas and other malignant epithelial neoplasms. http://seer.cancer.gov/publications2001
  72. Hung WSN. Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: a review. Thyroid. 2002;12:683–702
  73. Jarzab B, Handkiewicz-Junak D, Wloch J. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocr Relat Cancer. 2005;12:773–803
  74. Rachmiel M, Charron M, Gupta A, et al. Evidence-based review of treatment and follow up of pediatric patients with differentiated thyroid carcinoma. J Pediatr Endocrinol Metab. 2006;19:1377–1393
  75. Zimmerman D, Lteif AN. Thyrotoxicosis in children. Endocrinol Metab Clin North Am. 1998;27:109–126
  76. van Tol KM, de Vries EG, Dullaart RP, et al. Differentiated thyroid carcinoma in the elderly. Crit Rev Oncol Hematol. 2001;38:79–91
  77. Bliss R, Patel N, Guinea A, et al. Age is no contraindication to thyroid surgery. Age Ageing. 1999;28:363–366
  78. Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol. 2007;8:148–156
  79. Fagin JA. Challenging dogma in thyroid cancer molecular genetics—role of RET/PTC and BRAF in tumor initiation. J Clin Endocrinol Metab. 2004;89:4264–4266
  80. Trovisco V, Soares P, Sobrinho-Simoes M. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol. 2006;37:781–786
  81. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90:6373–6379
  82. Knauf JA, Kuroda H, Basu S, et al. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene. 2003;22:4406–4412
  83. Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194–202
  84. Kitazono M, Robey R, Zhan Z, et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab. 2001;86:3430–3435
  85. Milano A, Chiofalo MG, Basile M, et al. New molecular targeted therapies in thyroid cancer. Anticancer Drugs. 2006;17:869–879
  86. Cohen EE, Vokes EE, Rosen LS, et al. A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers. J Clin Oncol. 2007;25(Suppl 18, abstr):6008
  87. Sherman SI, Schlumberger MJ, Droz J, et al. Initial results from a phase II trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC). J Clin Oncol. 2007;25(Suppl 18, abstr):6017
  88. Kloos R, Ringel M, Knopp M, et al. Significant clinical and biologic activity of RAF/VEGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC): Updated results of a phase II study. J Clin Oncol. 2006;24(Suppl 18, abstr):5534
  89. Gupta V, Pattaswamy K, Lassoued W, et al. Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma. J Clin Oncol. 2007;25(Suppl 18, abstr):6019
  90. Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial. J Clin Oncol. 2007;25(Suppl 18, abstr):6018

PII: S0093-7754(08)00074-2

doi: 10.1053/j.seminoncol.2008.03.011

Seminars in Oncology
Volume 35, Issue 3 , Pages 298-308 , June 2008

Article Tools

* Image Usage & Resolution